Ligand-based drug discovery No a priori knowledge of the receptor What information can we get from a few active compounds.

Slides:



Advertisements
Similar presentations
Design of high-content and focused libraries to improve the development of new active compounds in the framework of the rational drug discovery Design.
Advertisements

3D Molecular Structures C371 Fall Morgan Algorithm (Leach & Gillet, p. 8)
Ionization and dissociation of drugs-1
PharmaMiner: Geometric Mining of Pharmacophores 1.
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Lipinski’s rule of five
…ask more of your data 1 Bayesian Learning Build a model which estimates the likelihood that a given data sample is from a "good" subset of a larger set.
Cheminformatics II Apr 2010 Postgrad course on Comp Chem Noel M. O’Boyle.
Quantative Structure- Activity Relationships. Why QSAR? The number of compounds required for synthesis in order to place 10 different groups in 4 positions.
Quantitative Structure-Activity Relationships (QSAR) Comparative Molecular Field Analysis (CoMFA) Gijs Schaftenaar.
Bioinformatics IV Quantitative Structure-Activity Relationships (QSAR) and Comparative Molecular Field Analysis (CoMFA) Martin Ott.
Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May
Structural biology and drug design: An overview Olivier Taboureau Assitant professor Chemoinformatics group-CBS-DTU
Chemoinformatics in Drug Design
Structure-based Drug Design
Quantitative Structure-Activity Relationships (QSAR)  Attempts to identify and quantitate physicochemical properties of a drug in relation to its biological.
Lecture 7: Computer aided drug design: Statistical approach. Lecture 7: Computer aided drug design: Statistical approach. Chen Yu Zong Department of Computational.
QSAR Qualitative Structure-Activity Relationships Can one predict activity (or properties in QSPR) simply on the basis of knowledge of the structure of.
GGAGATTCTGGGCCACTTTGGTTCCCCATGAGCCAAGACGGCACTTCTAATTTGCATTCCCTACCGGAGTCCCTGTCTGTAGCCAGCCTGGCTTTCAGCTGGTGCCCAAAGTGACAAATGTATCTGCAATGACAAAGGTAC CCTGGAAGGGCTCGCCCTCTGCGGAATTTCAGTTCATGCAGGCCTTGGTGCTTCCACATCTGTCCAAGGGCCTTTCAAATGTGACTTTTAACTCTGTGGATTGATTTGCCCGG
Pharmacophore and FTrees
Drug Design Process Discovery Phase. Tripos Software n SYBYL & its modules SYBYL, Concord, MOLCAD, SiteId, Advanced Computation, GASP, DISCOtech, HQSAR,
Computational Techniques in Support of Drug Discovery October 2, 2002 Jeffrey Wolbach, Ph. D.
Molecular Descriptors
Functional groups / Pharmacological Activity
BINF6201/8201 Principle components analysis (PCA) -- Visualization of amino acids using their physico-chemical properties
Topological Summaries: Using Graphs for Chemical Searching and Mining Graphs are a flexible & unifying model Scalable similarity searches through novel.
A genetic algorithm for structure based de-novo design Scott C.-H. Pegg, Jose J. Haresco & Irwin D. Kuntz February 21, 2006.
Introduction to Chemoinformatics Irene Kouskoumvekaki Associate Professor December 12th, 2012 Biological Sequence Analysis course.
Designing a Tri-Peptide based HIV-1 protease inhibitor Presented by, Sushil Kumar Singh IBAB,Bangalore Submitted to Dr. Indira Ghosh AstraZeneca India.
Faculté de Chimie, ULP, Strasbourg, FRANCE
3D- QSAR. QSAR A QSAR is a mathematical relationship between a biological activity of a molecular system and its physicochemical parameters. QSAR attempts.
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
Altman et al. JACS 2008, Presented By Swati Jain.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
Alessandro Pedretti MetaPies, an annotated database for metabolism analysis and prediction: results and future perspectives L’Aquila November 21, 2011.
Homework 2 (due We, Feb. 1): Reading: Van Holde, Chapter 1 Van Holde Chapter 3.1 to 3.3 Van Holde Chapter 2 (we’ll go through Chapters 1 and 3 first. 1.Van.
Pharmacophores Chapter 13 Part 2.
Selecting Diverse Sets of Compounds C371 Fall 2004.
Computer-aided drug discovery (CADD)/design methods have played a major role in the development of therapeutically important small molecules for several.
PharmaMiner: Geometric Mining of Pharmacophores 1.
Structure- based Structure-based computer-aided drug discovery (SB-CADD) approach: helps to design and evaluate the quality, in terms of affinity, of series.
Introduction to Chemoinformatics and Drug Discovery Irene Kouskoumvekaki Associate Professor February 15 th, 2013.
Bioinformatics in Drug Design and Discovery Unit 2.
Part 2. Physicochemical Properties 1.Rules ( 양혜란 ) 2.Liphophilicity ( 백아름 ) 3.pKa ( 박숙진 ) 4.Solubility ( 전종수, 최영재 ) 5.Permeability ( 김소연, 강경태 )
Computational Approach for Combinatorial Library Design Journal club-1 Sushil Kumar Singh IBAB, Bangalore.
Molecular mechanics Classical physics, treats atoms as spheres Calculations are rapid, even for large molecules Useful for studying conformations Cannot.
Elon Yariv Graduate student in Prof. Nir Ben-Tal’s lab Department of Biochemistry and Molecular Biology, Tel Aviv University.
Introduction to Biophysics Lecture 3 Molecular forces in Biological Structures.
Molecular Modeling in Drug Discovery: an Overview
Structure and Properties of Organic Molecules
Julia Salas CS379a Aim of the Study To determine distinguishing features of orally administered drugs –Physical and structural features probed.
SMA5422: Special Topics in Biotechnology Lecture 11: Computer aided drug design: QSAR approach. SMA5422: Special Topics in Biotechnology Lecture 11: Computer.
Natural products from plants
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Lipinski’s rule of five
Introduction-2 Important molecular interactions in Biomolecules
Physical Properties of Molecules
Daylight and Discovery
Virtual Screening.
Rules for Rapid Property Profiling from Structure
CZ3253: Computer Aided Drug design Lecture 4: Structural modeling of chemical molecules Prof. Chen Yu Zong Tel:
Volume 19, Issue 1, Pages (January 2012)
Volume 3, Issue 3, Pages (March 1999)
Giovanni Settanni, Antonino Cattaneo, Paolo Carloni 
What makes a molecule an anaesthetic
Derivation of preliminary three-dimensional pharmacophoric maps for chemically diverse intravenous general anaesthetics†   J.C. Sewell, J.W. Sear  British.
New compounds with improved biological activity
Volume 6, Issue 1, Pages (July 2000)
ORGANIC PHARMACEUTICAL CHEMISTRY IV
Patrick: An Introduction to Medicinal Chemistry 6e
Presentation transcript:

Ligand-based drug discovery No a priori knowledge of the receptor What information can we get from a few active compounds

Lipinski’s “rule of 5”: most drugs have less than two violation of the following rules: * ≤ 10 hydrogen bond acceptors * ≤ 5 hydrogen bond donors * Molecular weight ≤ 500 A partition coefficient log P ≤ 5 (non-original paper)” 2-8 rotatable bonds (entropy) Lipinski et al. Advanced Drug Delivery Reviews Volume 46, Issues 1-3, 1 March 2001, Pages benzene = 1.39 methanol = -.32 phenol = 1.4 Drug-likeness: what makes a drug a drug? ~30% exceptions. E.g., taxol

Hit development makes compounds larger and more complicated: violations of rule-of-5 criteria Need to start from lower values that “drug-like”: development of lead-like criteria Today: Design lead-like libraries for vHTS Even screen “probes”, scaffolds

Correlates physico-chemical properties of ligands with biological activity Calculation of Molecular descriptors: The Subdivided Surface Areas are descriptors based on an approximate accessible van der Waals surface area calculation for each atom, vi along with some other atomic property, pi. The vi is calculated using a connection table approximation. Each descriptor in a series is defined to be the sum of the vi over all atoms, i such that pi is in a specified range (a,b]. In the descriptions to follow, Li denotes the contribution to logP(o/w) for atom i as calculated in the SlogP descriptor [Crippen 1999]. Ri denotes the contribution to Molar Refractivity for atom i as calculated in the SMR descriptor [Crippen 1999]. The ranges were determined by percentile subdivision over a large collection of compounds. Code Description SlogP_VSA0 Sum of vi such that Li <= SlogP_VSA1 Sum of vi such that Li is in (-0.4,-0.2]. SlogP_VSA2 Sum of vi such that Li is in (-0.2,0]. SlogP_VSA3 Sum of vi such that Li is in (0,0.1]. SlogP_VSA4 Sum of vi such that Li is in (0.1,0.15]. SlogP_VSA5 Sum of vi such that Li is in (0.15,0.20]. SlogP_VSA6 Sum of vi such that Li is in (0.20,0.25]. apol Sum of the atomic polarizabilities (including implicit hydrogens) with polarizabilities taken from [CRC 1994]. bpol Sum of the absolute value of the difference between atomic polarizabilities of all bonded atoms in the molecule (including implicit hydrogens) with polarizabilities taken from [CRC 1994]. FCharge Total charge of the molecule (sum of formal charges). mr Molecular refractivity (including implicit hydrogens). This property is calculated from an 11 descriptor linear model [MREF 1998] with r2 = 0.997, RMSE = on 1,947 small molecules. a_aro Number of aromatic atoms. a_count Number of atoms (including implicit hydrogens) a_heavy Number of heavy atoms mWMolecular weight physical properties esoterism balabanJ Balaban's connectivity topological index [Balaban 1982] weinerPol Wiener polarity number: half the sum of all the distance matrix entries with a value of 3 as defined in [Balaban 1979]. delirium tremens QSAR:Build-up on known actives. About 30 actives, a few log units in activity

15 learning set 60 applications Drug optimisation : qsar Exemple with 75 compounds. Activity = log (blood/brain barrier) logBB = * petitjean * diameter * petitjeanSC * radius * VDistEq * VDistMa * weinerPath * weinerPol * BCUT_PEOE_ * BCUT_PEOE_ * BCUT_PEOE_ * BCUT_PEOE_ * BCUT_SLOGP_ * BCUT_SLOGP_ * BCUT_SLOGP_ * BCUT_SLOGP_ * BCUT_SMR_ * BCUT_SMR_ * BCUT_SMR_ * BCUT_SMR_3

60 learning set 15 applications

Apply model on larger database Would screen down the # of molecules to consider further for, e.g, synthesis, purchase, biology screening, structure-based screening etc… low logPhigh SloP

Ex: serotonine inhibitors Non descriptors-based : pharmacophore approaches superposed actives inactives Active superimpose “better” Can we quantify & rationalize that? inactivesactives

From aligned molecules : define pharmacophores Consensus among most actives

Testing and further development of pharmacophore model

Green: Steric bulk favored Yellow Yellow: Steric bulk disfavored Blue: Positive charge and H-bond donors favored Negative charge and H-bond acceptors disfavored Red: Negative charge and H-bond acceptors favored Positive charge and H-bond donors disfavore COMFA (“inverse” pharmacophore Pharmacophore of receptor

TARGET Use of receptor pharmacophore for receptor-selection: what protein could accommodate a given ligand. Chemical Biology, target discovery, proteome exploration etc….

Chemical space and molecular similarity/diversity 275 molecules, about 25 actives 3D representation of 5D PCA reduction of receptor- based QSAR green: most active, purple: moderate, blue: inactive

diversity In a large database, select compounds that exhibit most differences in properties: maximize chemical diversity Diversity -> focused. Chemical-space-based drug discovery: O Fishing with a large net in a large lake, use a smaller net where fish is found